Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI)

Glorieux, F. H.; Devogelaer, Jean-Pierre; Bishop, N.; Bober, M.; Brain, C. E.; Fekete, G.; Forin, V.; Hopkin, R. J.; Kaitila, I.; Lee, B.; Lorenc, R.; Mahan, J. D.; McCallister, J. A.; Pettifor, J. M.; Plotkin, H.; Rauch, F.; Salusky, I. B.; Shaw, N.; Showalter, L.; Steelman, J. W.

Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI)

Glorieux, F. H.

;

Devogelaer, Jean-Pierre

;

Bishop, N.

;

Bober, M.

;

Bucci-Rechtweg, C.

;et.al.

(2008)

Files

No attached file found for this publication.

Details

Authors

Glorieux, F. H.
Author
Devogelaer, Jean-PierreUCLouvain
Author
Bishop, N.
Author
Bober, M.
Author
Bucci-Rechtweg, C.
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvain

Citations

APA
Chicago
FWB

Glorieux, F. H., Devogelaer, J.-P., Bishop, N., Bober, M., Brain, C. E., Fekete, G., Forin, V., Hopkin, R. J., Kaitila, I., Lee, B., Lorenc, R., Mahan, J. D., McCallister, J. A., Pettifor, J. M., Plotkin, H., Rauch, F., Salusky, I. B., Shaw, N., Showalter, L., et al. (2008). Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI). Calcified Tissue International, 82, S85-S85. (Original work published 2008)